Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.83 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | APEX1 | P27695 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 6/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5607699 | 1.00 | TSHR (0.83) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL22554400 | 1.00 | TSHR (0.83) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL3502350 | 1.00 | TSHR (0.83) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL22554423 | 1.00 | TSHR (0.83) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL22023212 | 1.00 | TSHR (0.83) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL22554404 | 1.00 | TSHR (0.83) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL22554427 | 1.00 | TSHR (0.83) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL22554429 | 1.00 | TSHR (0.83) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL22554406 | 1.00 | TSHR (0.83) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL3503496 | 1.00 | TSHR (0.83) | TSHRTHRBPOLBAPEX1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111712523-B | Ophthalmic product composition | 爱尔兰眼力健公司 | 2023-01-03 | — | — | CN | claimed |
| EP-3728339-B1 | COMPOSITION FOR OPHTHALMOLOGICAL PRODUCTS | AMO Ireland (IE) | 2022-07-06 | — | — | EP | claimed |
| US-11359031-B2 | Composition for ophthalmological products | Johnson & Johnson Surgical Vision, Inc. (US) | 2022-06-14 | — | — | US | claimed |
| EP-3728339-A1 | COMPOSITION FOR OPHTHALMOLOGICAL PRODUCTS | Merck Patent GmbH (DE) | 2020-10-28 | — | — | EP | claimed |
| US-20200332041-A1 | COMPOSITION FOR OPHTHALMOLOGICAL PRODUCTS | MERCK PATENT GMBH (DE) | 2020-10-22 | — | — | US | claimed |
| CN-111712523-A | Ophthalmic product composition | 默克专利股份有限公司 | 2020-09-25 | — | — | CN | claimed |
| EP-4182737-B1 | OPTICALLY ACTIVE DEVICES | AMO Ireland (IE) | 2024-07-03 | — | — | EP | disclosed |
| US-20240142665-A1 | OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2024-05-02 | — | — | US | disclosed |
| US-20240117092-A1 | OPTICALLY ACTIVE DEVICES | AMO Ireland (IE) | 2024-04-11 | — | — | US | disclosed |
| EP-4284787-A1 | OPTICALLY ACTIVE DEVICES | AMO Ireland (IE) | 2023-12-06 | — | — | EP | disclosed |
| EP-4263513-A1 | OPTICALLY ACTIVE DEVICES | AMO Ireland (IE) | 2023-10-25 | — | — | EP | disclosed |
| US-20230273456-A1 | OPTICALLY ACTIVE DEVICES | JOHNSON & JOHNSON SURGICAL VISION INC (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230273455-A1 | OPTICALLY ACTIVE DEVICES | JOHNSON & JOHNSON SURGICAL VISION INC (US) | 2023-08-31 | — | — | US | disclosed |
| WO-2022128832-A1 | OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2022-06-23 | — | — | WO | disclosed |
| EP-4015512-A1 | OPTICALLY ACTIVE DEVICES | AMO Ireland (IE) | 2022-06-22 | — | — | EP | disclosed |
| US-11359031-B2 | Composition for ophthalmological products | Johnson & Johnson Surgical Vision, Inc. (US) | 2022-06-14 | — | — | US | disclosed |
| WO-2022012798-A1 | OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2022-01-20 | — | — | WO | disclosed |
| WO-2022012799-A1 | OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2022-01-20 | — | — | WO | disclosed |
| US-20200332041-A1 | COMPOSITION FOR OPHTHALMOLOGICAL PRODUCTS | MERCK PATENT GMBH (DE) | 2020-10-22 | — | — | US | disclosed |
| CN-111712523-A | Ophthalmic product composition | 默克专利股份有限公司 | 2020-09-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230273456-A1 | OPTICALLY ACTIVE DEVICES | PDE6C, PDE6D, PDE6A | TSHR 4585/4885THRB 4699/4885POLB 1579/4885 |
| US-20230273455-A1 | OPTICALLY ACTIVE DEVICES | PDE6C, PDE6A, PDE6D | TSHR 4592/4885THRB 4667/4885POLB 1376/4885 |
| US-20240117092-A1 | OPTICALLY ACTIVE DEVICES | PDE6C, UACA, PDE6A | TSHR 4604/4885THRB 4655/4885POLB 1077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.